EcoR1 Capital, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001587114

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2025 · 30 positions · Total reported value $2.08B · Top-10 concentration 80.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 55.3% · 9 new · 5 cut · 7 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +32.8% · vs SPY +18.0% · Prev Value $2.12B — last quarter positions weighted by this quarter price moves · ranking

In its Q3 2025 13F filing, EcoR1 Capital, LLC disclosed 30 equity positions with a combined reported value of $2.08B. The filing implies a focused portfolio: its ten largest positions account for 80.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2025 were ZYME ($392.33M), ANAB ($241.29M), QURE ($232.84M). By sector, the heaviest allocations are Health Care 81.8%, Other 18.2%. Versus the prior quarter, allocation shifted toward Health Care (+15.4pp) and away from Other (-15.0pp).

Versus the prior quarter, EcoR1 Capital, LLC opened 9 new positions, trimmed 5 and fully exited 7, a turnover rate of 55.3% of positions. The portfolio's overlap with the prior quarter was 57% of names.

The largest new positions opened in Q3 2025 were BBOT ($32.69M), AQST ($14.67M), CNTA ($13.34M).

Of the 7 positions fully exited versus the prior quarter, the largest were ITOS ($106.57M), JANX ($33.95M), AKRO ($23.48M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2025)

  • BBOT BridgeBio Oncology Therapeutic Inc · $32.69M
  • AQST AQUESTIVE THERAPEUTICS INC · $14.67M
  • CNTA CENTESSA PHARMACEUTICALS PLC · $13.34M
  • PRME PRIME MEDICINE INC · $8.55M
  • PEPG PEPGEN INC · $3.70M
  • CMPS COMPASS PATHWAYS PLC · $1.52M

Fully Exited (vs previous quarter)

  • ITOS ITEOS THERAPEUTICS INC · prev qtr: $106.57M
  • JANX JANUX THERAPEUTICS INC · prev qtr: $33.95M
  • AKRO AKERO THERAPEUTICS INC · prev qtr: $23.48M
  • VRNA VERONA PHARMA PLC · prev qtr: $18.92M
  • TECX TECTONIC THERAPEUTIC INCORPORATED · prev qtr: $18.58M
  • PCRX PACIRA BIOSCIENCES INC · prev qtr: $10.93M
  • REPL REPLIMUNE GROUP INC · prev qtr: $7.90M
  • ADAPY ADAPTIMMUNE THERAPEUTICS PLC · prev qtr: $6.57M

Insider Transactions (Form 4)

Latest EcoR1 Capital, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-05-07 Buy Atara Biotherapeutics, Inc. 507,407 $9.35 SEC filing
2026-04-20 Sell First Tracks Biotherapeutics, Inc. 4,705,575 $13.81 SEC filing

All insider transactions →

Fund Profile

EcoR1 Capital, LLC, based in San Francisco, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 31 positions worth $1.95B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: SAN FRANCISCO, CA, United States
  • SEC registration: 801-100470 (status: Approved), registered 2015-07-02
  • Regulatory AUM (Form ADV): $3.42B as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 2 hedge funds

Portfolio Structure

  • 31 positions · $1.95B reported value (Q2 2026)
  • Top 10 holdings = 87.7% of reported value
  • Largest position: ZYME (ZYMEWORKS INC) at 30.8%
  • Average position size: $62.85M

Sector Tilt

  • Health Care 97.3%
  • Financials 0.1%
  • (classified holdings cover 97% of value)

Quarterly Activity

  • Q2 2026: 9 new, 2 added, 5 reduced, 7 exited
  • 15 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 81.8%
Other 18.2%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 22.97M $392.33M 18.83%
18.83%
Hold
2 7.88M $241.29M 11.58%
11.58%
Hold
3 3.99M $232.84M 11.17%
11.17%
Add
4 1.71M $224.91M 10.79%
10.79%
Hold
5 4.29M $178.60M 8.57%
8.57%
Hold
6 1.39M $90.04M 4.32%
4.32%
Hold
7 10.63M $89.30M 4.29%
4.29%
Hold
8 6.73M $80.74M 3.87%
3.87%
Add
9 3.45M $78.01M 3.74%
3.74%
Reduce
10 6.14M $72.08M 3.46%
3.46%
Hold
11 1.67M $57.75M 2.77%
2.77%
Add
12 4.08M $47.77M 2.29%
2.29%
Hold
13 2.03M $44.12M 2.12%
2.12%
Hold
14 2.12M $37.16M 1.78%
1.78%
Add
15 75.00K $34.40M 1.65%
1.65%
Hold
16 765.00K $33.33M 1.60%
1.60%
Add
17 2.82M $32.69M 1.57%
1.57%
New
18 1.27M $22.03M 1.06%
1.06%
Hold
19 500.00K $15.00M 0.72%
0.72%
Hold
20 2.62M $14.67M 0.70%
0.70%
New
21 271.53K $14.21M 0.68%
0.68%
Hold
22 550.00K $13.34M 0.64%
0.64%
New
23 1.54M $8.55M 0.41%
0.41%
New
24 573.18K $8.21M 0.39%
0.39%
Hold
25 872.50K $7.72M 0.37%
0.37%
Reduce
26 800.00K $3.70M 0.18%
0.18%
New
27 963.33K $3.56M 0.17%
0.17%
Hold
28 670.30K $3.13M 0.15%
0.15%
Reduce
29 265.14K $1.52M 0.07%
0.07%
New
30 66.67K $859.31K 0.04%
0.04%
Hold

FAQ

What did EcoR1 Capital, LLC buy in 2025-Q3?

In its 2025-Q3 13F filing, EcoR1 Capital, LLC reported 30 equity positions worth $2.08B in aggregate; its largest disclosed positions were ZYME ($392.33M), ANAB ($241.29M), QURE ($232.84M).

How large is EcoR1 Capital, LLC's portfolio?

EcoR1 Capital, LLC reported $2.08B of long equity holdings across 30 positions as of 2025-Q3. Top-10 holdings account for 80.6% of reported value.

What is EcoR1 Capital, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/ecor1-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →